ImmunityBio, Inc.IBRXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +5333.09% | +41192.50% | +2423.88% | +425.07% | +406.95% |
| Gross Profit Growth | +5333.09% | +41047.50% | +2410.89% | +357.47% | +350.72% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +24.12% | +26.80% | +29.30% | +36.03% | +34.98% |
| Weighted Average Shares Diluted Growth | +24.34% | +26.80% | +29.30% | +35.62% | +34.73% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -16.26% | +716.71% | +983.98% | +553.22% | +1506.37% |
| Inventory Growth | +0.00% | +0.00% | +266.65% | -100.00% | -100.00% |
| Asset Growth | -24.09% | -24.19% | -9.51% | +42.36% | +31.07% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -30.62% | -28.04% | -27.23% | -27.01% | +74.17% |
| R&D Expense Growth | -31.65% | -9.59% | +8.03% | +0.57% | +72.65% |
| SG&A Expenses Growth | +26.04% | -22.04% | -14.04% | -8.59% | -9.34% |